Copper Fox Metals Inc
Change company Symbol lookup
Select an option...
CPFXF Copper Fox Metals Inc
DDAIF Daimler AG
REI Ring Energy Inc
CZSVF Goldcore Resources Ltd
AAPL Apple Inc
PMBC Pacific Mercantile Bancorp
MSFT Microsoft Corp
O Realty Income Corp
CRLBF Cresco Labs Inc
KSDIX Keeley Small Cap Dividend Value Fund Class I
Go

Materials : Metals & Mining | Small Cap Blend
Based in Canada
Company profile

Copper Fox Metals Inc. is a development-stage company. The Company operates as an exploration and development resource company. It is focused on the exploration and development of copper projects in North America. The Company primary assets are its interest in the Schaft Creek Joint Venture with Teck Resources Limited (Teck) on the Schaft Creek copper-gold-molybdenum-silver project located in northwestern British Columbia and the Van Dyke oxide copper deposit located in Globe-Miami Mining District in Arizona. The Company's Sombrero Butte project is located in the Laramide age porphyry copper belt in Arizona. The Company's Mineral Mountain project occurs along the Jemez structural trend that hosts the Miami-Globe, Resolution, Florence and Casa Grande copper deposits/districts. The Mineral Mountain property is located between the Florence copper deposit and the Resolution copper deposit. It also holds interest in Eaglehead Project, which is a copper-gold-molybdenum-silver property.

Closing Price
$0.3117
Day's Change
-0.015 (-4.61%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.338
Day's Low
0.2989
Volume
(Light)
Volume:
72,024

10-day average volume:
140,154
72,024

Shares of Corvus jump on additional data from small Phase 1 trial for COVID-19 treatment

8:05 am ET October 5, 2020 (MarketWatch)
Print

Shares of Corvus Pharmaceuticals Inc. (CRVS) gained 39.1% in premarket trading on Monday after the company shared additional interim details from a very small, early-stage clinical trial that indicates its experimental immunotherapy could produce antibodies and T-cells in some COVID-19 patients. The open-label, Phase 1 study has tested at three doses in 15 patients and plans to enroll a total of 30 patients with mild to moderate forms of the disease. A preprint (https://www.medrxiv.org/content/10.1101/2020.09.10.20191486v1) published in September had outlined initial results for two of the doses in 10 patients. (A preprint has not been peer-reviewed.) The company on Monday released data for five additional patients. Full results from the Phase 1 trial are expected to be released before the end of the year. Corvus' stock is down 25.2% so far this year, while the S&P 500 has gained 3.6%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 05, 2020 08:05 ET (12:05 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.